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Abstract
Background: Bisphosphonate (BP)-associated osteonecrosis of the jaw (ONJ) has been reported in patients
receiving intravenous BP, particularly zoledronic acid (ZA). The purpose of this study was to develop an in vitro
model representative of the effects BP has on soft tissue secondary to its release from bone. Human gingival
fibroblasts and oral epithelial cell lines were exposed to various concentrations (0-10 μM) of ZA using dentine discs
(DDs) as a direct carrier of BP, which were exposed for 24 hours to ZA in normal medium (NM), washed in
phosphate-buffered saline (PBS) and placed in a new co-culture with the cells. The cells were allowed to proliferate
until they grew over the bone discs and then the discs either were left unchelated, or were chelated using 0.001%
EDTA or EGTA to release BP from the discs and to observe the cellular effects. Direct effects were determined
using direct and fluorescent imaging. Apoptotic effects were determined by vital stain, terminal dUTP nick-end
labeling, and annexin V studies. The effect on cell proliferation was determined by mitochondrial tetrazolium salt
assay. The level of BP release was determined based on the effect of BP directly on cells, using the DDs or the
supernatant fluids resulting from chelation.
Results: A dose-response effect was seen on imaging, and effects on apoptosis and cell proliferation were
observed with increasing ZA concentrations liberated from the DDs, particularly after calcium cleavage and release
of ZA from the DDs with a variety of chelating agents. Apoptotic effects were observed microscopically after
chelation at 24 hours. Release of ZA was confirmed by extracting medium from non-chelated and chelated cell
culture models with DDs and applying this medium to untreated fresh cell cultures, providing appropriate controls.
Conclusions: The results from this study demonstrate that low concentrations of ZA released from bone can
rapidly and directly affect the oral mucosal tissues, initially through the induction of apoptosis and long term
through the inhibition of cell proliferation. These findings provide an in vitro model for a soft-tissue mechanistic
component in the initiation and/or progression of ONJ.
Background
Bisphosphonates (BP) are synthetic analogues of the
naturally occurring pyrophosphate, which are able to
chelate calcium ions [1-3]. Zoledronic acid (ZA), a
third-generation, nitrogen-containing BP, is one of the
most potent available [4,5]. Its high affinity for calcium
crystals allows this pyrophosphate to bind hydroxyapa-
tite of bone and inhibit osteoclast-mediated bone
resorption, a property that has provided the rationale
for their use as skeletal protectors of cancer-mediated,
cytokine-induced hypercalcemia [1-3,6,7]. In addition to
malignancies such as multiple myeloma [8] and solid
tumors at various stages [3], other specific conditions
such as osteoporosis [4] and Paget’s disease have been
the focus for BP therapy.
One of the more recently reported serious adverse
effects of ZA treatment is osteonecrosis of the jaw
(ONJ), a condition first recognized in 2003 as a compli-
cation associated with BP therapy [9] and originally
thought to involve the anti-angiogenic effects of ZA
[10-12]. The reported incidence of ONJ ranges from
1.3% to 19%, with a higher frequency in the mandible
than in the maxilla [13-21]. ONJ occurs in a dose- and
time-dependent manner, with cases being more preva-
lent in patients receiving intravenous (IV) dosing and
for longer periods of (10-59 months) [13-18]. Although
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ZA is known to preferentially deposit in areas of bone
formation, the pathophysiologic mechanisms of ONJ are
not fully elucidated [22]. One hypothesis suggested that
the microenvironment surrounding active osteoclasts is
strongly acidic, inducing the release of the BP from the
bone surface and creating high local BP concentrations
[2].
After administration of a single IV dose (2-16 mg) of
ZA, most of the drug is plasma-bound, with 40% of the
dose recovered in the urine within 24 hours, provided
there is normal renal function. The plasma half-life
ranges from 0 to 87 hours, with terminal elimination
lasting up to 146 hours. The remainder of the dose is
presumed to be bound to the bone, where it is slowly
released over time, resulting in low plasma levels
[23,24]. Currently, the oral mucosal levels of ZA are
unknown; however, various studies suggest a range of 1-
10 μM/L peak plasma concentrations after a 15 minute
IV infusion, with higher concentrations expected in the
bony microenvironment [25-27]. Recently, we developed
a novel bioassay measuring the levels of BP released
from discarded ONJ bone, using chelation with EDTA
and EGTA as the mechanism for release [28]. In this
study, we measured local levels of BP corresponding to
approximately 0.4 to 4.5 μM in bone in patients taking
BP [28]. These synthetic calcium chelators result in free
BP in the supernatant fluids, which is capable of indu-
cing apoptosis and suppressing cell proliferation com-
pared with controls. The chelating agents (EDTA and
EGTA) were selected to mimic the effects that saliva
may have on the release of BP from bone, so that we
could prove that when bound to bone or calcium, BP is
harmless, but when released by competitive chelation,
the free BP acts directly on the mucosal cells. This has
been proven by our previous work and confirmed
recently [29]. Importantly, our model has appropriate
controls for the use of EDTA and EGTA.
In approximately 60% of cases of ONJ, there is a
reported previous dental procedure or trauma; however,
up to 40% of patients with ONJ have no such history. In
fact, many of the cases of ONJ occur at sites away from
teeth on otherwise normal undisturbed tissues [13,30].
The fact that ONJ occurs as both a wound-healing phe-
nomenon and a spontaneous occurrence supports our
suggestion that the pathogenesis is probably
multifactorial.
Reid et al. [31] initially suggested the possibility of
soft-tissue toxicity from BP in a 2007 editorial. This
concept conforms to the clinical condition most com-
monly known as ONJ, which is observed as a mucosal
dehiscence leading to the formation of a superficial
mucosal ulcer, which progresses and results in detect-
able bone exposure. The ulcerated area continues to
extend with time, leading to bone necrosis and
sequestration [14]. We hypothesize that this effect
occurs through the localized release of free BP from the
bone surface, raising the concentration of BP in the
interface microenvironment between bone, periosteal
cells and the oral mucosa. This results in the apoptosis
of mucosal cells and exposure of bone to the oral
microbial environment, resulting in a mild to moderate
surface osteomyelitis and prolonged ONJ.
Our model provides an in vitro mechanism for study-
ing the initial effect of ZA release from bone on cells of
the oral mucosa; that is, the highly specialized cell lines
derived from oral epithelial and gingival fibroblast cells.
We selected concentrations of ZA that are representa-
tive of the clinical plasma levels predicted after any IV
infusion to validate our model and confirm our hypoth-
esis that the direct effects of low levels of ZA released
from bone induce mucosal cell apoptosis and inhibit
cellular proliferation. This model may constitute an
initiating mechanism for ONJ. In this study, we assessed
the apoptotic and proliferative effects of ZA release
from our bone model on oral mucosal cells.
Results
ZA-induced apoptosis and cell-growth inhibition
Initial analysis of apoptosis, fluorescent confirmation with
rhodamine
Physical signs of apoptosis were assayed in individual
human gingival fibroblast (HGF) (Figure 1a) and HaCaT
(Figure 1b) cells exposed to dentine discs (DDs) treated
with NM alone (control) or ZA (0.5, 1, 3 or 5 μM),
which either were left unchelated (Figure 1a,b; top rows)
or exposed to EDTA 0.001% (chelated) (Figure 1a,b; bot-
tom rows), Results were determined using fluorescent
microscopy on rhodamine-stained cells. A negative con-
trol for the effects of chelators on cells did not produce
any change in apoptotic patterns or in proliferation for
either cell line. At 24 hours in the non-chelated model,
only a few HGF (5 μM) and HaCaT (3 and 5 μM) cells
appeared to aggregate, fragment, and begin showing
dead floating cells, indicating apoptosis. By contrast, the
chelated model, representing ZA released from bone,
showed HGF and HaCaT cells entering apoptosis at a
low concentration of ZA (0.5 μM), and there was a
marked ring of dead cells visible at 3 and 5 μM (repre-
sentative concentrations shown).
Vital stain to confirm cell death
To confirm that the physical signs of apoptosis seen
using fluorescent rhodamine actually indicated cell
death, individual HGF and HaCaT cells exposed to NM
(control) or ZA (0.5, 1, 3 or 5 μM) DDs, which either
were chelated (EDTA 0.001%) or non-chelated, were
examined using vital stain and confocal microscopy. At
24 hours, both HGF (5 μM; Figure 2a, top rows) and
HaCaT (3 and 5 μM; Figure 2b, top rows) cultures
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Figure 1 Microscopical analysis of apoptosis in cells stained with rhodamine. Fluorescent microscopy images of (a) human gingival
fibroblast (HGF) and (b) HaCaT cells stained with rhodamine, which had been incubated with DDs treated with either normal medium (NM)
with infusion solution or ZA 1 or 5 μM (shown as red fluorescence at the right of the image) and then either left unchelated (top rows) or
exposed to EDTA 0.001% (chelated) (bottom rows). Images show the aggregation and breakdown of cells, both indicators of apoptosis, after
exposure to DDs treated with ZA for 24 h and chelated. Cells were observed over 24 hours with images taken at 24 hours (original
magnification ×400).
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Figure 2 Vital stain. Confocal microscopy of (a) human gingival fibroblast (HGF) and (b) HaCaT cells exposed to DDs treated with either
normal medium (NM) with infusion solution or ZA 1 or 5 μM (shown as a lack of fluorescence at the right of the image) and either left
unchelated (top rows) or exposed to EDTA 0.001% (chelated) (bottom rows). Images show cells that are viable (green), cells initiating cell death
(yellow) and cells that are dying (red) Cells were observed over 24 hours with images taken at 24 hours (original magnification ×400).
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showed only a few cells initiating cell death (yellow) and
dying (red) in the non-chelated model (12 and 25 cells
per high power field (HPF), respectively). By contrast,
the chelated model showed both HGF (Figure 2a, bot-
tom rows) and HaCaT (Figure 2b, bottom rows) cells
entering cell death at ZA 1 μM, with a marked ring of
dead cells apparent at ZA 3 and 5 μM (HGF: 168 and
74 cells per HPF; HaCaT: 82 and 93 cells per HPF,
respectively) (representative concentrations shown).
Confirmation of apoptosis
The dose dependent-increase in apoptosis in the ZA-
treated HGF and HaCaT cells observed by microscopy
was corroborated by the results from terminal uridine
deoxynucleotidyl transferase (dUTP) nick end labeling
(Figure 3a,b) and annexin V (Figure 4a) flow cytometry
apoptosis assays. Initial confirmation of apoptosis was
made using TUNEL assay with HGF and HaCaT cells
exposed to DDs treated with NM (control) or ZA (0.5,
1, 3 or 5 μM), which were chelated (EDTA 0.001%) or
non-chelated, and viewed by fluorescent microscopy. At
24 hours, at ZA 5 μM, only a few cells were initiating
cell death (21 cells per HPF; green) in the non-chelated
model (Figure 3a, top rows), whereas in the chelated
model, cells started entering cell death at 1 μM (68 cells
per HPF), with a marked ring of dead cells apparent at
3 and 5 μM (98 and 147 cells per HPF, respectively)
(Figure 3a, bottom rows; shows effects on HGF cells,
representative concentrations shown).
Proving proof of principle, a TUNEL assay was per-
formed where DDs only (no cells) treated with either
NM (control) or ZA (0.5, 1, 3 or 5 μM) for 24 hours
and then chelated (EDTA 0.001%) for 24 hours. Sec-
ondly, the medium from the treated DDs was removed
and applied to fresh HaCaT cells for 24 hours, then
assayed by TUNEL, and viewed by fluorescent micro-
scopy. The HaCaT cells treated with the medium
alone from ZA-treated and chelated DDs showed
an incrementally increased number of cells entering
apoptosis (25, 52, 43 and 182 cells per HPF, respec-
tively) (Figure 3b).
Finally, an annexin V apoptosis assay was performed.
First, DDs only (no cells) treated with either NM (con-
trol) or ZA (0.5, 1, 3, 5 or 10 μM), and either chelated
(EDTA 0.001%) or non-chelated, were assayed. Secondly,
the medium from the chelated or non-chelated DDs was
removed and applied to fresh HGF or HaCaT cells for
24 hours. Both fresh HGF and HaCaT cells exposed to
medium from non-chelated DDs treated with ZA
demonstrated an increase in apoptosis (HGF: 2.97%,
3.19%, 3.42% and 3.39% increase for HGF and 1.75%,
5.27%, 5.79% and 8.32% increase for HaCaT at ZA 1, 3,
5 and 10 μM, respectively) compared with the NM con-
trol (raw data score of control cultures were averaged
over three separate runs: 156 and 352 cells per 10,000
events in HGF and HaCaT cells respectively). Cells
exposed to medium from chelated DDs had a larger
increase (3.89%, 3.88%, 3.98%, 4.97% and 5.3% increase
for HGF and 9.88%, 9.69%, 11.22%, 12.91% and 12.83%
for HaCaT at ZA 0.5, 1, 3, 5 and 10 μM, respectively)
compared with the NM control (raw data score of con-
trol cultures were averaged over three separate runs:
194 and 272 cells per 10,000 events in HGF and HaCaT
cells respectively) (Figure 4a). The differences between
non-chelated and chelated DDs were significant (P <
0.05) for HaCaT cells at all four concentrations of ZA
(0.5, 1, 3 and 5 μM).
Cell proliferation
Cell proliferation using mitochondrial tetrazolium salt
(MTS) assay was performed on both cell lines using
DDs treated with either NM (control) or ZA (0.5, 1, 3, 5
or 10 μM, and either chelated (EDTA or EGTA 0.001%)
or non-chelated. Secondly, the medium from the che-
lated or non-chelated DDs was removed and applied to
fresh HaCaT cells for 24 hours. Results at 24 hours
showed that fresh HaCaT cells exposed to medium from
non-chelated DDs treated with ZA (0.5, 1, 3, 5 and 10
μM) failed to demonstrate a significant difference in cell
proliferation from the NM control (raw data score of
control cultures were averaged over three separate runs:
156 and 352 cells per 10,000 events in HGF and HaCaT
cells respectively)(Figure 4b). The chelated models of
fresh HaCaT cells exposed for 24 hours to medium
from chelated DDs demonstrated a combined decrease
in cell proliferation (12%, 14%, 19.4%, 19.9% decrease at
ZA 1, 3, 5 and 10 μM, respectively) compared with the
NM control (raw data score of control cultures were
averaged over three separate runs: 156 and 352 cells per
10,000 events in HGF and HaCaT cells respectively)
(Figure 4b). The level of ZA released from the DDs was
determined by comparing levels of ZA in the medium
with the effects on cell proliferation induced by direct
addition of ZA from our previous studies [14,28,32]. We
found that levels of ZA released from DDs secondary to
chelation with EDTA/EGTA to be equivalent to 0, 0.25,
.075, 0.87, 0.96 and 0.98 μM on average at ZA concen-
trations of 0, 0.5, 1, 3, 5 and 10 μM, respectively, for
both chelation methods. Significant differences from
controls were seen in the chelated DD model starting at
the 1 μM level, whereas cells treated directly with ZA
were significantly different from controls at the 0.5 μM
level (P < 0.05). The non-chelated DDs never demon-
strated significant differences from NM controls.
Discussion
Currently, over 190 million prescriptions oral BP are
dispensed worldwide, with an increasing incidence of
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Figure 3 Apoptosis. Terminal dUTP nick end labeling assay. (a) Fluorescent microscopy images of human gingival fibroblast (HGF) cells exposed
to DDs treated with either normal medium (NM) with infusion solution or ZA 1 or 5 μM (green area of fluorescence at the right of the image)
and either left unchelated (top rows) or exposed to EDTA 0.001% (chelated) (bottom rows). (b) Alternate TUNEL assay was performed in HaCaT
cells using first, DDs treated with either normal medium or 0.5, 1 or 5 μM of ZA and exposed to EDTA 0.001% (chelated). Secondly, the medium
from the treated DDs was removed and applied to fresh HaCaT cells for 24 hours, followed by TUNEL assay and images using fluorescent
microscopy. Cells were observed over 24 hours with images taken at 24 hours. Original magnification (a) ×200; (b) × 400.
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reported cases of ONJ [33]. Most reported cases of ONJ
(94%) are in patients receiving intravenous BPs for sup-
portive cancer care [18], particularly patients with multi-
ple myeloma, metastatic prostate cancer and metastatic
breast cancer. Recently, however, cases of ONJ were also
reported in patients treated with oral alendronate for
osteoporosis [18]. The use of the IV formulation of ZA
every 3 to 4 weeks appears to be associated with the
greatest risk for developing ONJ [18,30]. However, the
exact mechanism by which this occurs is not yet known
[34]. It is hypothesized that the skeleton acts as a reser-
voir of BP that produces high concentrations located
within the vicinity of the bone [27]. Interestingly,
treatment of osteoclasts, monocytes and tumor cells
with BP in solution leads to cell death, indicating that
resorption of bone is not required for cellular BP
uptake. Osteoclasts treated with BP are shown to lose
function to the same degree as those exposed to BP-
treated bone slices, indicating that bone resorption is
not necessary for BP action [35].
In this study, we developed an in vitro model showing
for the first time proof of and the mechanism for a soft-
tissue component of ONJ, whereby after release from
bone, BP induces gingival fibroblast and epithelial cell
death via apoptosis, with the continued release of ZA pre-
venting spontaneous resolution or healing, due to
Figure 4 Annexin V. (a) Annexin V apoptosis assay was performed in human gingival fibroblast (HGF) and HaCaT cells. First DDs treated with
either normal medium in infusion solution (NM) or ZA 0.5, 1, 3, 5 or 10 μM and either left unchelated or exposed to EDTA 0.001% (chelated)
were assayed. Secondly, the medium from the non-chelated (NC) or chelated (C) DDs was removed and applied to fresh HGF or HaCaT cells for
24 hours. (b) Cell proliferation results using mitochondrial tetrazolium salt (MTS) assay. First, DDs treated with either normal medium in infusion
solution (NM) or ZA 0.5, 1, 3, 5 or 10 μM and either left unchelated or exposed to EDTA or EGTA 0.001% (chelated) were assayed. Secondly, the
medium from the non-chelated (NC) or chelated (C-EDTA or C-EGTA) DDs was removed and applied to fresh HaCaT cells for 24 hours. Error bars
indicate SEM. The growth of cells in NM was set as the control. *Significant (P < 0.05) differences from control cells.
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inhibition of cell proliferation. Recognizing various poten-
tial chelating interactions with the surrounding mucosal
and osseous tissues, we believe this process results in
increased mucosal cell apoptosis, leading to eventual
thinning and exposure of bone, allowing for rapid micro-
bial colonization [36]. The formation of a biofilm smear
layer would create an environment of mild to moderate
osteomyelitis, preventing the resolution of inflammation
and healing in the oral cavity, therefore leading to persis-
tent ONJ [36]. Additionally, calcium chelators in saliva
may produce a localized release of BP, further inducing
cell apoptosis and providing a mechanism that would
explain the prolonged length of bone exposure and failure
of healing [32,37]. Microscopy, TUNEL, vital stain and
annexin V studies demonstrated that ZA chelated from
DDs leads to dose-dependent apoptotic processes in
human epithelial (HaCaT) and fibroblast (HGF) cells.
These data point to a direct effect of ZA on epithelium
and fibroblasts in a temporal sequence that begins at very
low concentrations (1 μm) of BP in the fibroblasts, and
then proceeds to the epithelial cells.
Interestingly, in this model, proliferation studies
demonstrated a reduced amount of cell growth inhibi-
tion with up to 10 μM ZA, in contrast to previous stu-
dies, which showed significant inhibition at 1-5 μM
[28,32,37]. A possible explanation for this discrepancy is
the amount of ZA released upon chelation from the
DDs. Currently, a mechanism to detect the level of ZA
in medium, saliva, bone or blood does not exist. Our
model uses a mechanism to determine the maximum
dose of ZA administered, assuming that the level may
be lower than that applied to the DDs. However, with
this in mind we have shown that levels potentially lower
than those previously shown can induce changes in the
oral mucosa that are sufficient to produce mucosal
dehiscence and ONJ lesions [28,32]. Confirming this,
the annexin V assays using medium from chelated ZA-
treated DDs produced significant apoptosis in fresh
mucosal cells not exposed to DDs.
Our in vitro model supports our hypothesis that ONJ
occurs via a combined mechanism, including bone, sys-
temic and soft-tissue mechanisms. The bony mechanism
is believed to occur secondary to an alteration of angio-
genesis of new osseous tissue, inducing detrimental
effects on the quality and quantity of bone perfusion,
and ultimately leading to an altered response of osseous
tissue to trauma, infection and wound healing [35].
Incorporation of the systemic alterations caused by the
additional pharmacologic therapies that this type of
patient must undergo, would prevent exposed bone
from fighting infections in the oral cavity, perpetuating
the risk of ONJ [38]. Finally, the release of BP from
bone secondary to calcium chelation could initiate the
process via mucosal dehiscence.
Further studies are needed to fully elucidate this
model, including the biochemical mechanisms, the effect
on dual cell lines of epithelial and fibroblast origin and
the effect of induced osteoclasts, and to determine if
such effects are clinically relevant for in vivo models of
ONJ.
Conclusions
The importance of this study rests on the fact that only
empirical treatment is currently employed for ONJ. Cur-
rently, preventive strategies aimed at avoiding invasive
oral interventions such as dental surgery and subsequent
infection are the standard of care. Additionally, it is
recommended that until healing from an invasive dental
surgical treatment takes place, temporary discontinua-
tion of BP therapy (up to 3 months) may be considered
[39,40]; however there is no prospective evidence that
this affects outcome. These weakly supported treatment
recommendations flow from a clinical paradigm and fail
to follow a causative mechanism. We provide for the
first time an in vitro model showing that the direct con-
tact of clinically relevant concentrations of ZA with
epithelial or fibroblast cells induces apoptosis and pre-
vents cell proliferation, with the potential result being
ONJ. It is our expectation that expanding this in vitro
model, including oral microbes, will produce a model
mimicking the oral environment, so as to conceive and
design specific interventions, and produce in vivo studies
to determine oral ZA levels in crevicular and salivary
fluids, which will further confirm this hypothesis.
Methods
Cell lines and cell cultures
All experiments were performed using an established
human keratinocyte cell line (HaCaT) and a human gin-
gival fibroblast cell line (HGF) (donated by Dr Silvio
Gutkind at the National Institutes of Health and John
Sauk at University of Maryland, respectively), selected as
cells representative of the unique oral mucosa. Other
researchers have observed the effects of BP on murine
oral keratinocytes, cancer cells and osteoclasts, showing
cell line apoptosis and/or decreased cell proliferation
[41-46]; however, these studies were not specific to the
disease process, and because ONJ is a specific disease
state, we chose specific native cell lines for our model.
Cells were cultured in (i) Dulbecco modified Eagle med-
ium (DMEM) with 10% fetal bovine serum (FBS), peni-
cillin 100 U and streptomycin 100 μg/ml or (ii) a 1:1
mix of Ham F12 and DMEM with 10% FBS, penicillin
100 U, streptomycin 100 μg/ml and hydrocortisone1.0
mg/ml (Sigma Chemical Company, St. Louis, MO,
USA), respectively. The cells were cultured at 37°C in a
5% CO2 in air atmosphere until confluent, and subcul-
tured using a disaggregation assay with trypsin 0.1% and
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EDTA 0.01% in PBS (pH 7.5). For all experiments, cells
were grown in 6-, 24-, 48- or 96-well plates at 5 × 104
cells per well and grown to 80% to 90% confluence.
Control cells (in NM) were treated for all experiments
with the infusion solution (0.36% saline, which did not
contain calcium) alone in NM, in accordance with the
manufacturer’s directions. Saline was used to closely
mimic the true infused drug used in the clinical setting.
All experiments were performed in triplicate, and
repeated on two separate occasions.
Drug treatments
Injectable ZA (Zometa; Novartis Pharmaceuticals Corp,
East Hanover, NJ, US) was selected for these studies
because it is the most widely reported BP associated
with ONJ. The model established here is applicable to
further investigations with all types of BP. ZA was used
for all experiments at six different concentrations
(0, 0.5, 1, 3, 5, 10 μM), These concentrations were
selected because they are clinically relevant to patients
receiving ZA, being representative of the lower limits of
estimated plasma concentrations after a 15-minute infu-
sion (baseline plasma concentration level is 1 μM).
First, ZA was diluted to the appropriate concentration
in NM. For each drug concentration, one DD (our
mimic of bone) (IDS Ltd., Bolden, Tyne and Wear, UK),
was used. The DDs were immersed in the drug in
48-well plates for 24 hours. They were then removed
from the normal or ZA-containing medium, washed
three times in PBS and inserted into 6- or 24-well
plates containing fresh medium without ZA added.
Next, HaCaT or HGF cells were plated into the same
wells as the DDs and allowed to grow onto and around
the DDs to 90% confluence. The ZA (0.5 to 10 μM)
treated and untreated (ZA 0 μM) DDs were then either
left unchelated or were chelated using EDTA or EGTA
at 0.001%. The chelating agents were selected for their
known activity and their simulation of the oral environ-
ment, as various components of saliva are capable of
chelation. EDTA and EGTA were selected to validate
our model, as the additional components of saliva
might confound our in vitro model. Cells were visua-
lized, photographed and assayed during the 24 hour
treatment, with images collected showing the zone of
apoptosis surrounding the DDs. Controls for the use of
EDTA and EGTA were DDs pretreated in NM alone
without ZA, which showed minimal apoptosis.
Direct microscopical observation
Adherent HaCaT and HGF cell lines were plated in
fresh medium (no ZA) overlying and surrounding either
untreated (NM) or treated DDs (ZA 0.5, 1, 3 or 5 μM
concentration diluted in infusion solution), which were
then either left unchelated or were chelated using
EDTA 0.001% for 24 hours. Cells were examined under
a microscope (Axiovert 135; Zeiss, Thornwood, NY,
USA) hourly for up to 24 hours (images not shown).
Rhodamine assay
Adherent HaCaT and HGF cell lines were plated into
fresh medium (no ZA) overlying and surrounding either
untreated (NM) or treated DDs (0.5, 1, 3 or 5 μM ZA
diluted in infusion solution), which were then either left
unchelated or were chelated using EDTA 0.001% for 24
hours. After 24 hours, cells were washed twice with PBS
and fixed with a solution of 4% paraformaldehyde in
PBS pH 7.4 for 1 h at 20°C. Cells were rinsed twice with
PBS and then incubated with permeabilisation solution
for 2 minutes on ice. The cells were rinsed in PBS and
labeled with rhodamine for 30 minutes, rinsed twice
with PBS, and examined under a fluorescent microscope
with a detection range of 515 to 565 nm.
TUNEL staining
Adherent HaCaT and HGF cell lines were plated into
fresh medium (no ZA) overlying and surrounding either
untreated (NM) or treated DDs (0.5, 1, 3 or 5 μM ZA
diluted in infusion solution), which were then either left
unchelated or were chelated using EDTA 0.001% for 24
hours. Cells were washed twice with PBS and fixed with
a fixation solution of paraformaldehyde 4% in PBS pH
7.4 for 1 h at 20°C. Cells were rinsed twice with PBS
and then incubated with permeabilisation solution for 2
minutes on ice. The cells were rinsed in PBS and labeled
using 50 μl of a 9:1 solution of ‘Label and Enzyme solu-
tion’ (In Situ Cell Death Detection Kit, Fluorescein;
Roche Applied Sciences, Mannheim, Germany), with
appropriate controls labeled only with the Label solu-
tion. The cells were incubated for 1 h at 37°C in a
humidified atmosphere in the dark, rinsed in PBS, and
examined under a fluorescent microscope with a detec-
tion range of 515 to 565 nm.
Vital stain
Adherent HaCaT and HGF cell lines were plated in
fresh medium (no ZA) overlying and surrounding either
untreated (NM) or treated DDs (0.5, 1, 3 or 5 μM ZA
diluted in infusion solution), which were then either
unchelated or were chelated using EDTA 0.001%.for
24 hours. Cells were washed twice with PBS and stained
to evaluate cell membrane integrity (BacLight Vital
Bacterial Viability Kit; cat. no. L-7012; Molecular Probes,
Eugene, OR, USA). The kit contains Syto9 to detect
cells with intact membranes (live) and propidium iodide
to identify membrane-damaged cells (dead) [47] The
stain was prepared by dilution of 3 μl of each compo-
nent into 1 ml of Tris-EDTA buffer (pH 7.0). Confocal
microscopy was used to analyze the rate of cell death.
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Flow cytometry and annexin V studies
Apoptosis was evaluated using annexin V conjugated
with fluorescein isothiocyanate. DDs alone were placed
in 48-well plates with either untreated (NM) or treated
(ZA of 0.5, 1, 3, 5 or 10 μM concentration diluted in
fresh medium with infusion solution) medium for 24 h.
After 24 h, the DDs were removed, washed three times
in PBS and placed in new 6-well plates with fresh med-
ium (no ZA) and either were left unchelated or were
chelated using EDTA 0.001% for 24 hours. In separate
6-well plates (no DD), HaCaT and HGF cells were
grown to 80% confluency. Cells were washed with
Hank’s balanced salt solution (HBSS) and then treated
using the medium only from the initially untreated or
ZA-treated and non-chelated or chelated DD wells.
Next, the cells were washed twice with PBS and washed
with HBSS, followed by lysis using 0.1% trypsin and
0.01% EDTA in PBS pH 7.5. The cells were washed with
cold PBS and resuspended in 1× binding buffer (BD-
Pharmingen Biosciences, San Diego, CA, USA), then
5 μl of annexin and 5 ml of propidium iodide were
added to the cells, which were then mixed by vortex
and incubated for 15 minutes in the dark. Finally, 400
ml of 1× binding buffer was added, and samples were
evaluated by flow cytometry (Epics Elite ESP Flow Cyt-
ometer; Beckman Coulter, Brea, CA, USA).
Cell proliferation
Proliferation was performed by non-radioactive MTS
cell proliferation assay (Promega, Madison, WI, USA).
DDs alone were placed in 48-well plates and either left
untreated (NM) or treated with ZA (0.5, 1, 3, 5 or 10 μM
concentration diluted in fresh medium with infusion
solution) for 24 hours. The DDs were then removed,
washed three times in PBS and placed in new 6-well
plates with fresh medium (no ZA) and either were left
unchelated or were chelated using EDTA or EGTA
0.001% for 24 hours. HaCaT cells were separately
plated by themselves in 96-well plates using a density of
2,500 cells/well and allowed to grow to 80% confluence.
Cells were washed with HBSS and then treated using the
medium only from the initially untreated or ZA treated
and then non-chelated or chelated DDs. The cells were
then examined by MTS cell proliferation assay, which
was read at a wavelength of 570 nm (96-well MR4000
Microplate Palate Reader; Dynatech, Chantilly, VA,
USA). The percentage cell growth was determined by
setting as 100% the growth of control cells treated only
with infusion solution in NM. All analyses were per-
formed in triplicate and repeated on separate occasions.
Statistical analysis
For all measurements, as needed, t-test or Student’s
t-test or was used to assess significance of treated
groups versus control groups. P < 0.05 was considered
significant, and data are presented as means ± SEM.
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